A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-To-Mesenchymal Transition

Total Page:16

File Type:pdf, Size:1020Kb

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-To-Mesenchymal Transition Published OnlineFirst September 29, 2015; DOI: 10.1158/1078-0432.CCR-15-0876 Cancer Therapy: Preclinical Clinical Cancer Research A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition Milena P. Mak1,2, Pan Tong3, Lixia Diao3, Robert J. Cardnell1, Don L. Gibbons1,4, William N. William1, Ferdinandos Skoulidis1, Edwin R. Parra5, Jaime Rodriguez-Canales5, Ignacio I.Wistuba5, John V.Heymach1, John N.Weinstein3, Kevin R.Coombes6, Jing Wang3, and Lauren Averett Byers1 Abstract Purpose: We previously demonstrated the association between EMT markers across diverse tumor types and identifies differences epithelial-to-mesenchymal transition (EMT) and drug response in in drug sensitivity and global molecular alterations at the DNA, lung cancer using an EMT signature derived in cancer cell lines. RNA, and protein levels. Among those changes associated with Given the contribution of tumor microenvironments to EMT, we EMT, pathway analysis revealed a strong correlation between EMT extended our investigation of EMT to patient tumors from 11 and immune activation. Further supervised analysis demonstrat- cancer types to develop a pan-cancer EMT signature. ed high expression of immune checkpoints and other druggable Experimental Design: Using the pan-cancer EMT signature, we immune targets, such as PD1, PD-L1, CTLA4, OX40L, and PD-L2, conducted an integrated, global analysis of genomic and prote- in tumors with the most mesenchymal EMT scores. Elevated omic profiles associated with EMT across 1,934 tumors including PD-L1 protein expression in mesenchymal tumors was confirmed breast, lung, colon, ovarian, and bladder cancers. Differences in by IHC in an independent lung cancer cohort. outcome and in vitro drug response corresponding to expression Conclusions: This new signature provides a novel, patient- of the pan-cancer EMT signature were also investigated. based, histology-independent tool for the investigation of EMT Results: Compared with the lung cancer EMT signature, the and offers insights into potential novel therapeutic targets for patient-derived, pan-cancer EMT signature encompasses a set of mesenchymal tumors, independent of cancer type, including core EMT genes that correlate even more strongly with known immune checkpoints. Clin Cancer Res; 1–12. Ó2015 AACR. Introduction phenotype, a process known as "epithelial-to-mesenchymal tran- sition" (EMT). Studies have shown that EMT plays an important Over the past decade, multiple lines of evidence have suggested biologic role in cancer progression, metastasis, and drug resistance that epithelial cancers can transform into a more mesenchymal (1–3). Tools that facilitate the study of EMT, therefore, will provide new insights into molecular regulation and evolution 1Department of Thoracic/Head and Neck Medical Oncology, The Uni- during oncogenesis and may help to improve treatments for versity of Texas MD Anderson Cancer Center, Houston,Texas. 2Medical mesenchymal cancers. The development of EMT signatures or Oncology, Instituto do Cancer do Estado de Sao Paulo, Faculdade de other molecular markers to identify whether a cancer has under- Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil. 3Depart- ment of Bioinformatics and Computational Biology, The University of gone EMT is an area of active research. Most studies in this area, Texas MD Anderson Cancer Center, Houston, Texas. 4Department of however, have focused on a single tumor type and/or on preclin- Molecular and Cellular Oncology,The University of Texas MDAnderson ical models (3–7). Cancer Center, Houston, Texas. 5Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer We previously developed a robust, platform-independent EMT Center, Houston, Texas. 6Department of Biomedical Informatics, Ohio signature based on a set of 54 lung cancer cell lines (hereafter State University, Columbus, Ohio. called the lung cancer EMT signature). In vitro, this lung cancer Note: Supplementary data for this article are available at Clinical Cancer EMT signature predicted resistance to EGFR and PI3K/Akt inhi- Research Online (http://clincancerres.aacrjournals.org/). bitors and identified AXL as a potential therapeutic target for M.P. Mak and P. Tong are co-first authors. overcoming resistance to EGFR inhibitors [a common treatment – Corresponding Authors: Lauren Averett Byers, The University of Texas MD for non small cell lung cancer (NSCLC)]. We and others observed fi Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0432, Houston, TX 77030. signi cantly greater resistance to EGFR inhibitors in lung cancers Phone: 713-792-6363; Fax: 713-792-1220; E-mail: [email protected]; and that had undergone EMT, as determined by either their baseline Jing Wang, Department of Bioinformatics and Computational Biology, The EMT signature (3) or the expression of specific EMT markers after University of Texas MD Anderson Cancer Center, Houston, TX. Phone: 713- the development of acquired EGFR inhibitor resistance (8). 794-4190; Fax: 713-563-4242; E-mail: [email protected] Although it is appealing to apply the lung cancer EMT signature doi: 10.1158/1078-0432.CCR-15-0876 to diverse tumor types, this approach may be limited by tumor Ó2015 American Association for Cancer Research. type-specific differences in EMT or discrepancies between cell line www.aacrjournals.org OF1 Downloaded from clincancerres.aacrjournals.org on September 26, 2021. © 2015 American Association for Cancer Research. Published OnlineFirst September 29, 2015; DOI: 10.1158/1078-0432.CCR-15-0876 Mak et al. CCLE by SNP fingerprinting at multiple steps, profiles were Translational Relevance compared with existing profiles (10, 11). We used level-3 TCGA Epithelial-to-mesenchymal transition (EMT) is associated pan-cancer data (12, 13), including RNAseqV2, reverse phase with resistance to many approved drugs and with tumor protein array (RPPA), miR, copy number, mutation, and clinical progression. Here, we sought to characterize the common data. A summary of the TCGA data can be found in Supplemen- biology of EMT across multiple tumor types and identify tary Table S1. The Profiling of Resistance Patterns and Oncogenic potential therapeutic vulnerabilities in mesenchymal tumors. Signaling Pathways in Evaluation of Cancers of the Thorax and A patient-derived, pan-cancer EMT signature was developed Therapeutic Target Identification (PROSPECT) dataset of surgi- using 11 distinct tumor types from The Cancer Genome Atlas. cally resected NSCLC has been previously described (9). Array- Mesenchymal tumors had similar patterns of gene, protein, based expression profiling of PROSPECT tumors was performed and miRNA expression independent of cancer type. Tumors using the Illumina Human WG-6 v3 BeadChip according to the with mesenchymal EMT scores not only had a higher expres- manufacturer's protocol and gene expression data have been sion of the receptor tyrosine kinase Axl (previously implicated previously deposited in the GEO repository (GSE42127). with EMT and associated with response to Axl inhibitors), but also expressed high levels of multiple immune checkpoints Developing the pan-cancer EMT signature including PD-L1, PD1, CTLA4, OX40L, and PD-L2. This novel We adopted an approach similar to that used by Byers and finding, which was validated in an independent patient colleagues (3) to derive the pan-cancer EMT signature. We used cohort, highlights the possibility of utilizing EMT status— four established EMT markers, namely, CDH1 (epithelial marker, independent of cancer type—as an additional selection tool to E type), CDH2 (mesenchymal marker, M type), VIM (M type), and select patients who may benefit from immune checkpoint FN1 (M type) as seeds to derive the pan-cancer EMT signature on blockade. the basis of TCGA pan-cancer RNAseq data. In particular, we computed correlations (Pearson correlation, r) between all mRNAs in the RNAseq data and each of the established EMT markers for each individual tumor type. models [the starting point of the lung cancer EMT signature (3)] fi and clinical patient samples—especially in regard to the interplay Identi cation of EMT-associated genomic features between EMT, tumor microenvironments, and immune response We computed Pearson correlation between the EMT score and at different disease sites (9). Therefore, we built upon our previous individual genomic features because these features are normally approach to derive a pan-cancer EMT signature by leveraging distributed. The genomic features per gene included the mRNA molecular datasets from 11 tumor types (n ¼ 1,934 tumors expression, RPPA expression (either total protein or phosphory- overall; see Supplementary Table S1) using clinical patient sam- lated protein), and miRNA expression levels (5p and 3p mature ples from The Cancer Genome Atlas (TCGA). The datasets were strands). obtained from primarily epithelial malignancies, such as breast, colorectal, and endometrial cancer, and two cohorts of lung Association between EMT score and other covariates cancer (adenocarcinoma and squamous cell carcinoma). We applied the log-rank test to assess the association between We tested the performance of the pan-cancer EMT signature by the dichotomized EMT score (with a cutoff of 0) and overall comparing its association with established, but independent, survival. We used the ANOVA test to assess the association EMT markers at the proteomic, microRNA (miRNA), and mRNA between EMT score and
Recommended publications
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • Phyre 2 Results for A1YIY0
    Email [email protected] Description A1YIY0 Tue Jul 30 13:19:15 BST Date 2013 Unique Job 1035bc4b501530df ID Detailed template information # Template Alignment Coverage 3D Model Confidence % i.d. Template Information PDB header:cell adhesion Chain: A: PDB Molecule:down syndrome cell adhesion molecule 1 c3dmkA_ Alignment 100.0 14 (dscam) isoform PDBTitle: crystal structure of down syndrome cell adhesion molecule (dscam)2 isoform 1.30.30, n-terminal eight ig domains PDB header:cell adhesion 2 c2om5A_ Alignment 100.0 20 Chain: A: PDB Molecule:contactin 2; PDBTitle: n-terminal fragment of human tax1 PDB header:cell adhesion 3 c3jxaA_ Alignment 100.0 21 Chain: A: PDB Molecule:contactin 4; PDBTitle: immunoglobulin domains 1-4 of mouse cntn4 PDB header:signaling protein/transferase Chain: A: PDB Molecule:tek tyrosine kinase variant; 4 c4k0vA_ 100.0 12 Alignment PDBTitle: structural basis for angiopoietin-1 mediated signaling initiation PDB header:immune system Chain: A: PDB Molecule:natural cytotoxicity triggering receptor 1; 5 c1p6fA_ 100.0 9 Alignment PDBTitle: structure of the human natural cytotoxicity receptor nkp46 PDB header:immune system/receptor 6 c1ollA_ Alignment 99.9 9 Chain: A: PDB Molecule:nk receptor; PDBTitle: extracellular region of the human receptor nkp46 PDB header:viral protein Chain: A: PDB Molecule:hoc head outer capsid protein; 7 c3shsA_ 99.9 18 Alignment PDBTitle: three n-terminal domains of the bacteriophage rb49 highly immunogenic2 outer capsid protein (hoc) PDB header:immune system Chain: E: PDB Molecule:natural
    [Show full text]
  • CD226 T Cells Expressing the Receptors TIGIT and Divergent Phenotypes of Human Regulatory
    The Journal of Immunology Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226 Christopher A. Fuhrman,*,1 Wen-I Yeh,*,1 Howard R. Seay,* Priya Saikumar Lakshmi,* Gaurav Chopra,† Lin Zhang,* Daniel J. Perry,* Stephanie A. McClymont,† Mahesh Yadav,† Maria-Cecilia Lopez,‡ Henry V. Baker,‡ Ying Zhang,x Yizheng Li,{ Maryann Whitley,{ David von Schack,x Mark A. Atkinson,* Jeffrey A. Bluestone,‡ and Todd M. Brusko* Regulatory T cells (Tregs) play a central role in counteracting inflammation and autoimmunity. A more complete understanding of cellular heterogeneity and the potential for lineage plasticity in human Treg subsets may identify markers of disease pathogenesis and facilitate the development of optimized cellular therapeutics. To better elucidate human Treg subsets, we conducted direct transcriptional profiling of CD4+FOXP3+Helios+ thymic-derived Tregs and CD4+FOXP3+Helios2 T cells, followed by comparison with CD4+FOXP32Helios2 T conventional cells. These analyses revealed that the coinhibitory receptor T cell Ig and ITIM domain (TIGIT) was highly expressed on thymic-derived Tregs. TIGIT and the costimulatory factor CD226 bind the common ligand CD155. Thus, we analyzed the cellular distribution and suppressive activity of isolated subsets of CD4+CD25+CD127lo/2 T cells expressing CD226 and/or TIGIT. We observed TIGIT is highly expressed and upregulated on Tregs after activation and in vitro expansion, and is associated with lineage stability and suppressive capacity. Conversely, the CD226+TIGIT2 population was associated with reduced Treg purity and suppressive capacity after expansion, along with a marked increase in IL-10 and effector cytokine production. These studies provide additional markers to delineate functionally distinct Treg subsets that may help direct cellular therapies and provide important phenotypic markers for assessing the role of Tregs in health and disease.
    [Show full text]
  • Single-Cell RNA Sequencing Demonstrates the Molecular and Cellular Reprogramming of Metastatic Lung Adenocarcinoma
    ARTICLE https://doi.org/10.1038/s41467-020-16164-1 OPEN Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Nayoung Kim 1,2,3,13, Hong Kwan Kim4,13, Kyungjong Lee 5,13, Yourae Hong 1,6, Jong Ho Cho4, Jung Won Choi7, Jung-Il Lee7, Yeon-Lim Suh8,BoMiKu9, Hye Hyeon Eum 1,2,3, Soyean Choi 1, Yoon-La Choi6,10,11, Je-Gun Joung1, Woong-Yang Park 1,2,6, Hyun Ae Jung12, Jong-Mu Sun12, Se-Hoon Lee12, ✉ ✉ Jin Seok Ahn12, Keunchil Park12, Myung-Ju Ahn 12 & Hae-Ock Lee 1,2,3,6 1234567890():,; Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we present single-cell tran- scriptome profiling of metastatic lung adenocarcinoma, the most prevalent histological lung cancer type diagnosed at stage IV in over 40% of all cases. From 208,506 cells populating the normal tissues or early to metastatic stage cancer in 44 patients, we identify a cancer cell subtype deviating from the normal differentiation trajectory and dominating the metastatic stage. In all stages, the stromal and immune cell dynamics reveal ontological and functional changes that create a pro-tumoral and immunosuppressive microenvironment. Normal resident myeloid cell populations are gradually replaced with monocyte-derived macrophages and dendritic cells, along with T-cell exhaustion. This extensive single-cell analysis enhances our understanding of molecular and cellular dynamics in metastatic lung cancer and reveals potential diagnostic and therapeutic targets in cancer-microenvironment interactions. 1 Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
    [Show full text]
  • An Ontogenetic Switch Drives the Positive and Negative Selection of B Cells
    An ontogenetic switch drives the positive and negative selection of B cells Xijin Xua, Mukta Deobagkar-Lelea, Katherine R. Bulla, Tanya L. Crockforda, Adam J. Meadb, Adam P. Cribbsc, David Simsc, Consuelo Anzilottia, and Richard J. Cornalla,1 aMedical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, OX3 9DS Oxford, United Kingdom; bMedical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, OX3 9DS Oxford, United Kingdom; and cMedical Research Council, Weatherall Institute of Molecular Medicine, Centre for Computational Biology, Weatherall Institute of Molecular Medicine, University of Oxford, OX3 9DS Oxford, United Kingdom Edited by Michael Reth, University of Freiburg, Freiburg, Germany, and approved January 6, 2020 (received for review September 3, 2019) + Developing B cells can be positively or negatively selected by self- BM HSCs increased CD5 B-1a B cell development (15), while antigens, but the mechanisms that determine these outcomes are expression of let-7b in FL pro-B cells blocked the development of incompletely understood. Here, we show that a B cell intrinsic B-1 B cells (17). These findings support the notion of hard-wired switch between positive and negative selection during ontogeny differences during ontogeny, but possibly downstream of the HSC is determined by a change from Lin28b to let-7 gene expression. commitment stage. Ectopic expression of a Lin28b transgene in murine B cells restored Several lines of evidence also suggest that B-1 B cells can un- the positive selection of autoreactive B-1 B cells by self-antigen in dergo positive selection, which is linked to their B cell receptor adult bone marrow.
    [Show full text]
  • B Cell Checkpoints in Autoimmune Rheumatic Diseases
    REVIEWS B cell checkpoints in autoimmune rheumatic diseases Samuel J. S. Rubin1,2,3, Michelle S. Bloom1,2,3 and William H. Robinson1,2,3* Abstract | B cells have important functions in the pathogenesis of autoimmune diseases, including autoimmune rheumatic diseases. In addition to producing autoantibodies, B cells contribute to autoimmunity by serving as professional antigen- presenting cells (APCs), producing cytokines, and through additional mechanisms. B cell activation and effector functions are regulated by immune checkpoints, including both activating and inhibitory checkpoint receptors that contribute to the regulation of B cell tolerance, activation, antigen presentation, T cell help, class switching, antibody production and cytokine production. The various activating checkpoint receptors include B cell activating receptors that engage with cognate receptors on T cells or other cells, as well as Toll-like receptors that can provide dual stimulation to B cells via co- engagement with the B cell receptor. Furthermore, various inhibitory checkpoint receptors, including B cell inhibitory receptors, have important functions in regulating B cell development, activation and effector functions. Therapeutically targeting B cell checkpoints represents a promising strategy for the treatment of a variety of autoimmune rheumatic diseases. Antibody- dependent B cells are multifunctional lymphocytes that contribute that serve as precursors to and thereby give rise to acti- cell- mediated cytotoxicity to the pathogenesis of autoimmune diseases
    [Show full text]
  • Binding Mode of the Side-By-Side Two-Igv Molecule CD226/DNAM-1 to Its Ligand CD155/Necl-5
    Binding mode of the side-by-side two-IgV molecule CD226/DNAM-1 to its ligand CD155/Necl-5 Han Wanga, Jianxun Qib, Shuijun Zhangb,1, Yan Lib, Shuguang Tanb,2, and George F. Gaoa,b,2 aResearch Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences (CAS), 100101 Beijing, China; and bCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, 100101 Beijing, China Edited by K. Christopher Garcia, Stanford University School of Medicine, Stanford, CA, and approved December 3, 2018 (received for review September 11, 2018) Natural killer (NK) cells are important component of innate immu- CD226, also known as DNAM-1, belongs to the Ig superfamily nity and also contribute to activating and reshaping the adaptive and contains two extracellular Ig-like domains (CD226-D1 and immune responses. The functions of NK cells are modulated by CD226-D2), and is widely expressed in monocytes, platelets, multiple inhibitory and stimulatory receptors. Among these recep- T cells, and most of the resting NK cells (8, 13, 19, 20). The tors, the activating receptor CD226 (DNAM-1) mediates NK cell intracellular domain of CD226 does not contain a tyrosine-based activation via binding to its nectin-like (Necl) family ligand, CD155 activation motif, which is accepted as responsible for activating (Necl-5). Here, we present a unique side-by-side arrangement signal transduction of stimulatory molecules (13). Instead, it pattern of two tandem immunoglobulin V-set (IgV) domains transmits the downstream signaling by phosphorylation of in- deriving from the ectodomains of both human CD226 (hCD226- tracellular phosphorylation sites and subsequent association with ecto) and mouse CD226 (mCD226-ecto), which is substantially integrin lymphocyte function-associated antigen 1 (21).
    [Show full text]
  • CD Markers Are Routinely Used for the Immunophenotyping of Cells
    ptglab.com 1 CD MARKER ANTIBODIES www.ptglab.com Introduction The cluster of differentiation (abbreviated as CD) is a protocol used for the identification and investigation of cell surface molecules. So-called CD markers are routinely used for the immunophenotyping of cells. Despite this use, they are not limited to roles in the immune system and perform a variety of roles in cell differentiation, adhesion, migration, blood clotting, gamete fertilization, amino acid transport and apoptosis, among many others. As such, Proteintech’s mini catalog featuring its antibodies targeting CD markers is applicable to a wide range of research disciplines. PRODUCT FOCUS PECAM1 Platelet endothelial cell adhesion of blood vessels – making up a large portion molecule-1 (PECAM1), also known as cluster of its intracellular junctions. PECAM-1 is also CD Number of differentiation 31 (CD31), is a member of present on the surface of hematopoietic the immunoglobulin gene superfamily of cell cells and immune cells including platelets, CD31 adhesion molecules. It is highly expressed monocytes, neutrophils, natural killer cells, on the surface of the endothelium – the thin megakaryocytes and some types of T-cell. Catalog Number layer of endothelial cells lining the interior 11256-1-AP Type Rabbit Polyclonal Applications ELISA, FC, IF, IHC, IP, WB 16 Publications Immunohistochemical of paraffin-embedded Figure 1: Immunofluorescence staining human hepatocirrhosis using PECAM1, CD31 of PECAM1 (11256-1-AP), Alexa 488 goat antibody (11265-1-AP) at a dilution of 1:50 anti-rabbit (green), and smooth muscle KD/KO Validated (40x objective). alpha-actin (red), courtesy of Nicola Smart. PECAM1: Customer Testimonial Nicola Smart, a cardiovascular researcher “As you can see [the immunostaining] is and a group leader at the University of extremely clean and specific [and] displays Oxford, has said of the PECAM1 antibody strong intercellular junction expression, (11265-1-AP) that it “worked beautifully as expected for a cell adhesion molecule.” on every occasion I’ve tried it.” Proteintech thanks Dr.
    [Show full text]
  • Urinary Biomarkers for the Detection of Prostate Cancer in Patients with High-Grade Prostatic Intraepithelial Neoplasia
    The Prostate Urinary Biomarkers for the Detection of Prostate Cancer in Patients With High-Grade Prostatic Intraepithelial Neoplasia Tamara Sequeiros,1 Juan M. Bastaros, 2 Milagros Sanchez, 1 Marina Rigau,1 Melania Montes,1 Jose Placer,2 Jaques Planas,2 Ines de Torres,3 Jaume Reventos, 1,4,5 D. Michiel Pegtel,6 Andreas Doll,1,4 Juan Morote,1,2 and Mireia Olivan1* 1Group of Biomedical Research in Urology, Vall d’Hebron Research Institute (VHIR) and Universitat Autonoma de Barcelona (UAB), Barcelona, Spain 2Department of Urology, Vall d’Hebron University Hospital and Universitat Autonoma de Barcelona (UAB), Barcelona, Spain 3Department of Pathology, Vall d’Hebron University Hospital and Universitat Autonoma de Barcelona (UAB), Barcelona, Spain 4Departament de Ciencies Basiques, Universitat Internacional de Catalunya, Barcelona, Spain 5IDIBELL- Bellvitge Biomedical Research Institute, Barcelona, Spain 6Department of Pathology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands INTRODUCTION. High-grade prostatic intraepithelial neoplasia (HGPIN) is a recognized precursor stage of PCa. Men who present HGPIN in a first prostate biopsy face years of active surveillance including repeat biopsies. This study aimed to identify non-invasive prognostic biomarkers that differentiate early on between indolent HGPIN cases and those that will transform into actual PCa. METHODS. We measured the expression of 21 candidate mRNA biomarkers using quantitative PCR in urine sediment samples from a cohort of 90 patients with initial diagnosis of HGPIN and a posterior follow up of at least two years. Uni- and multivariate statistical analyses were applied to analyze the candidate biomarkers and multiplex models using combinations of these biomarkers.
    [Show full text]
  • A20 Regulates the Therapeutic Effect of Anti-PD-1 Immunotherapy In
    Open access Original research J Immunother Cancer: first published as 10.1136/jitc-2020-001866 on 9 December 2020. Downloaded from A20 regulates the therapeutic effect of anti- PD-1 immunotherapy in melanoma Weinan Guo,1 Jinyuan Ma,1 Sen Guo,1 Huina Wang,1 Sijia Wang,1,2 Qiong Shi,1 Lin Liu,1 Tao Zhao,1 Fengfan Yang,3 Shuyang Chen,4 Jianru Chen,1 Jianhong Zhao,1 Chen Yu,1 Xiuli Yi,1 Yuqi Yang,1 Jingjing Ma,1 Qingrong Ni,1 Guannan Zhu,1 1 1 Tianwen Gao, Chunying Li To cite: Guo W, Ma J, Guo S, ABSTRACT (PD-1)/programmed death ligand 1 (PD-L1) et al. A20 regulates the Background The therapeutic effect of immune have been demonstrated as a pair of major therapeutic effect of anti- PD-1 checkpoint blockers, especially the neutralizing immunotherapy in melanoma. immune checkpoint molecules and valuable antibodies of programmed cell death (PD-1) and its ligand 1 Journal for ImmunoTherapy therapeutic targets for melanoma treatment. programmed death ligand 1 (PD-L1), has been well verified of Cancer 2020;8:e001866. For instance, the binding of membrane doi:10.1136/jitc-2020-001866 in melanoma. Nevertheless, the dissatisfactory response rate and the occurrence of resistance significantly hinder PD- L1 on tumor cells to PD-1 on T cells the treatment effect. Inflammation- related molecules like evokes an immunosuppressive signal that ► Additional material is results in the dysfunction and even the apop- published online only. To view A20 are greatly implicated in cancer immune response, please visit the journal online but the role of tumorous A20 in antitumor immunity and tosis of cytotoxic T cells, thereby impairing 2 (http:// dx.
    [Show full text]
  • Human Neonatal B Cell Immunity Differs from the Adult Version by Conserved Ig Repertoires and Rapid, but Transient Response Dynamics
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.11.245985; this version posted September 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Human neonatal B cell immunity differs from the adult version by conserved Ig repertoires and rapid, but transient response dynamics Bettina Budeus,1,# Artur Kibler,1,# Martina Brauser,1,# Ekaterina Homp,1,# Kevin Bronischewski,1 J. Alexander Ross,1 Andre Görgens,2,3 Marc A. Weniger,1 Josefine Dunst,4,5 Taras Kreslavsky,4,5 Symone Vitoriano da Conceição Castro,2,6 Florian Murke,2 Christopher C. Oakes,7,8 Peter Rusch,9 Dimitrios Andrikos,9 Peter Kern,9 Angela Köninger,9 Monika Lindemann,2 Patricia Johansson,10 Wiebke Hansen,11 Anna-Carin Lundell,12 Anna Rudin,12 Jan Dürig,10 Bernd Giebel,2 Daniel Hoffmann,13 Ralf Küppers,1 Marc Seifert1* 1Institute of Cell Biology (Cancer Research), Medical Faculty, University of Duisburg-Essen, 45147 Essen, Germany. 2Institute for Transfusion Medicine, Medical Faculty, University of Duisburg-Essen, Essen 45147, Germany. 3Department of Laboratory Medicine, Karolinska Institute, Stockholm 17177, Sweden. 4Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institute, Karolinska University Hospital, Stockholm 17177, Sweden. 5Center for Molecular Medicine, Karolinska Institute, Stockholm 17177, Sweden 6CAPES Foundation, Ministry of Education of Brazil, Brasília 70610-908, Brazil. 7Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH 43210, USA. 8Department of Biomedical Informatics, The Ohio State University, Columbus, OH 43210, USA. 9Department of Gynecology, Medical Faculty, University of Duisburg- Essen, Essen 45147, Germany.
    [Show full text]
  • In Prostate Cancer
    l ch cina em di is e tr M y Shen et al., Med chem 2014, 4:11 Medicinal chemistry DOI: 10.4172/2161-0444.1000220 ISSN: 2161-0444 Revie Article Open Access Roles of Serine Protease Inhibitor Kazal type 1 (SPINK1) in Prostate Cancer Chengwu Shen1, Jing Zhang1, Mei Qi2, Yannicca WYChang3 and Bo Han2,4* 1Department of Pharmacy, Shandong Provincial Hospital, Jinan 250021 China 2Department of Pathology, School of Medicine, Shandong University, Jinan 250012, China 3Department of Health and Disease and Psychology, University of Tornoto, Markham, Canada 4Department of Pathology, Qilu Hospital, Shandong University, Jinan 250012, China Abstract Altered genes that play a driving role in cancer development can often serve as specific diagnostic markers, criteria of molecular classification and therefore potential therapeutic targets. Serine protease inhibitor Kazal type 1 (SPINK1), also known as pancreatic secretory trypsin inhibitor or tumor-associated trypsin inhibitor, encodes a 56 amino acid secreted peptide, and its normal function is thought to be the inhibition of serine proteases such as trypsin. Recent studies have indicated marked overexpression of SPINK1 defines an aggressive molecular subtype of ETS (erythroblastosis virus E26 transformation-specific) fusion-negative prostate cancer ((PCa) patients. SPINK1 may act as an autocrine growth factor and promotes PCa growth and invasion. Most recently, we suggested that SPINK1 induces epithelial-mesenchymal transition (EMT) through EGFR signaling pathway in PCa. The association between SPINK1 overexpression and poor prognosis in PCa has been reported. Notably, SPINK1 might be a novel extracellular therapeutic target in a subset of high-grade PCa patients. In this review, we will summarize the current understanding of SPINK1 involving its role in PCa biology, association with prognosis as well as perspective in therapy from the pathologist's point of view.
    [Show full text]